After 70% Pricing OK’ed for Biosame, Nesp Biosimilar Developers Stay Pat on November Listing Plans

March 28, 2019
Two camps of companies developing Nesp (darbepoetin alfa) biosimilars are making no changes to their plans to get their products listed in November, they told Jiho on March 27, after a key panel agreed to price the biosame version of...read more